Kenvue Inc.(NYSE:KVUE) is experiencing substantial shifts within its shareholder base with various acquisitions and dispositions of Kenvue shares by financial institutions. Kenvue's price target has been cut to $20.00. Despite job cuts and the termination of Johnson & Johnson’s involvement with Kenvue, the company beat revenue expectations in Q1 2024. A win came via a court ruling in favour of the Band-Aid maker, which also forecasted profit below expectations due to drag on China. Its Cyber Tools were revamped post its spinoff from J&J. Product portfolio includes potential generics. It's noteworthy that Greenlight Capital, among others, has newly invested in the company, and it has plans for a secondary public offering. Kenvue aims to declare quarterly cash dividends and increase efficiencies within product development and marketing. Despite a challenging period, the company's fundamentals look strong. Yet, job cuts within the Neutrogena brand and the LA office are slated and the company maps out hundreds of layoffs.
Kenvue KVUE News Analytics from Thu, 19 Oct 2023 07:00:00 GMT to Sun, 21 Jul 2024 15:43:56 GMT -
Rating -3
- Innovation 2
- Information 7
- Rumor -4
